Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2025-08-22 00:00:00 ET · period of report 2025-08-21 · accession 0000950170-25-111011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-22 | 2025-08-21 | BBIO | Trimarchi Thomas | Pres, CFO | S - Sale | $49.48 | -42.2K | 421.1K | -9% | -$2.09M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-21 | S | D | 42,237 | $49.48 | 421,081 | D | — | — | (F1) Represents the weighted average sale price of the shares sold from $49.08 to $49.77 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |